Isis Pharmaceuticals Inc. (ISIS) and Genzyme (GENZ) announced data from the phase 3 study of mipomersen Tuesday morning, in patients with homozygous familial hypercholesterolemia. The study met its primary endpoint and also met each of its secondary endpoints. Isis Pharmaceuticals sharply declined until around the middle of Tuesday morning and finished down by $2.28 at $11.12 on the highest volume of the year. The stock sank below a 3-week range and closed at an 11-month low.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.